Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine + Venlafaxine in Severe Major Depressive Disorder
NCT01557712Phase 3Completed
- Sponsor
- CHU Grenoble Alpes
- Start
- Mar 2012
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ketamine in major depressive disorder (MDD), sponsored by CHU Grenoble Alpes. Started Mar 2012; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01557712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01557712.